Olga A. Martynova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Olga A. Martynova has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Vagan Bokhyan
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Yaroslav A. Zhulikov
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - Anna A. Roslyakova
Endocrinology Research Centre
2 shared publications - Elena I. Kovalenko
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Elena V. Kaytukova
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical University
2 shared publications - Maryam R. Tamrazova
Blokhin National Medical Research Center of Oncology
2 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 16 (2) , 99-108
Modern methods of treatment of anaplastic thyroid cancer (clinical case)
The article presents a clinical case of treating stage IV anaplastic thyroid cancer with a V600E mutation in the BRAF gene and distant metastasis (including metastases to the right ventricle of the heart and the right adrenal gland). At the first stage, targeted therapy (dabrafenib + trametinib) was performed, which allowed achieving pronounced clinico-metabolic regression and performing radical multi-stage surgical treatment. Subsequently, with the development of drug resistance and the detection of high expression of programmed cell death 1 ligand (PD-L1) (Combined Positive Score (CPS) – the ratio of the number of PD-L1-positive cells to the total number of tumor cells = 100), immunotargeted therapy with pembrolizumab in combination with lenvatinib was prescribed, resulting in a partial metabolic response. Despite the subsequent disease progression, overall survival from the time of diagnosis was 46 months. The presented clinical case demonstrates the importance of molecular profiling and the use of a multidisciplinary approach, as well as the possibility of using active surgical management in the oligoprogression of anaplastic thyroid cancer.
- 18 September 2026
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 16 (2) , 99-108
Open AccessModern methods of treatment of anaplastic thyroid cancer (clinical case)
The article presents a clinical case of treating stage IV anaplastic thyroid cancer with a V600E mutation in the BRAF gene and distant metastasis (including metastases to the right ventricle of the heart and the right adrenal gland). At the first stage, targeted therapy (dabrafenib + trametinib) was performed, which allowed achieving pronounced clinico-metabolic regression and performing radical multi-stage surgical treatment. Subsequently, with the development of drug resistance and the detection of high expression of programmed cell death 1 ligand (PD-L1) (Combined Positive Score (CPS) – the ratio of the number of PD-L1-positive cells to the total number of tumor cells = 100), immunotargeted therapy with pembrolizumab in combination with lenvatinib was prescribed, resulting in a partial metabolic response. Despite the subsequent disease progression, overall survival from the time of diagnosis was 46 months. The presented clinical case demonstrates the importance of molecular profiling and the use of a multidisciplinary approach, as well as the possibility of using active surgical management in the oligoprogression of anaplastic thyroid cancer.
- Open Access
- 29 July 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (2) , 191-196
Surgical treatment of pheochromocytoma complicated by tumor thrombosis of the inferior vena cava: a post-hoc analysis and series of clinical cases
Aim. To describe the surgical approach and evaluate the results of treatment in a series of cases of pheochromocytoma complicated by tumor thrombosis of the inferior vena cava (IVC). Materials and methods. The study presents the experience with surgical treatment of patients with pheochromocytoma complicated by IVC tumor thrombosis. From 1989 to 2024, 181 patients with pheochromocytoma underwent surgical treatment at the Blokhin National Medical Research Center of Oncology, of whom 7 (3.9%) had an IVC involvement. In 6 cases, the patients were males aged 17 to 73 years, and in 1 case, a female aged 66 years. In all cases, tumor thrombosis of the IVC was due to right-sided pheochromocytoma, including in 1 patient with bilateral adrenal gland involvement. Pheochromocytoma was diagnosed based on clinical, laboratory, and imaging data (CT scan, combined positron-emission and CT scan, and magnetic resonance imaging) and confirmed by histological and immunohistochemical studies. Surgical approach included radical removal of the tumor with thrombectomy from the IVC in 4 patients. In 2 cases, exploratory interventions were performed, and 1 patient received drug treatment. Particular attention is paid to the surgical procedure, which requires careful planning and an individual approach to each patient. The surgery includes the technique of removing blood clots with their full visualization due to the structure of tumor thrombi and the risk of fragmentation and embolism. Results. No postoperative mortality was reported. During follow-up (up to 5 years), no recurrence or progression was detected in the patients. Conclusion. Tumor thrombosis of the IVC in pheochromocytoma is uncommon. Surgery is the treatment of choice, providing radical tumor removal and achieving long-term remission in pheochromocytoma. Particular attention should be paid to the characteristics of the tumor thrombi, which, according to our observations, have a loose consistency and often a tight attachment to the vascular wall, increasing the risk of fragmentation. Therefore, thrombectomy should be performed with careful visualization and control of all thrombotic masses to minimize intraoperative embolism.
- 29 July 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (2) , 191-196
Open AccessSurgical treatment of pheochromocytoma complicated by tumor thrombosis of the inferior vena cava: a post-hoc analysis and series of clinical cases
Aim. To describe the surgical approach and evaluate the results of treatment in a series of cases of pheochromocytoma complicated by tumor thrombosis of the inferior vena cava (IVC). Materials and methods. The study presents the experience with surgical treatment of patients with pheochromocytoma complicated by IVC tumor thrombosis. From 1989 to 2024, 181 patients with pheochromocytoma underwent surgical treatment at the Blokhin National Medical Research Center of Oncology, of whom 7 (3.9%) had an IVC involvement. In 6 cases, the patients were males aged 17 to 73 years, and in 1 case, a female aged 66 years. In all cases, tumor thrombosis of the IVC was due to right-sided pheochromocytoma, including in 1 patient with bilateral adrenal gland involvement. Pheochromocytoma was diagnosed based on clinical, laboratory, and imaging data (CT scan, combined positron-emission and CT scan, and magnetic resonance imaging) and confirmed by histological and immunohistochemical studies. Surgical approach included radical removal of the tumor with thrombectomy from the IVC in 4 patients. In 2 cases, exploratory interventions were performed, and 1 patient received drug treatment. Particular attention is paid to the surgical procedure, which requires careful planning and an individual approach to each patient. The surgery includes the technique of removing blood clots with their full visualization due to the structure of tumor thrombi and the risk of fragmentation and embolism. Results. No postoperative mortality was reported. During follow-up (up to 5 years), no recurrence or progression was detected in the patients. Conclusion. Tumor thrombosis of the IVC in pheochromocytoma is uncommon. Surgery is the treatment of choice, providing radical tumor removal and achieving long-term remission in pheochromocytoma. Particular attention should be paid to the characteristics of the tumor thrombi, which, according to our observations, have a loose consistency and often a tight attachment to the vascular wall, increasing the risk of fragmentation. Therefore, thrombectomy should be performed with careful visualization and control of all thrombotic masses to minimize intraoperative embolism.
- Open Access
- 11 March 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (1)
Prospective, Single-Center, Phase II Study to Standardize the Mitotane Dosing Regimen in Combination with Platinum-Based Chemotherapy in the First-Line Treatment for Adrenocortical Cancer
Введение. Комбинация химиотерапии EDP (этопозида, доксорубицина, цисплатина) с митотаном является стандартом первой линии терапии адренокортикального рака (АКР). Достижение терапевтических концентраций митотана связано с улучшением выживаемости без прогрессирования (ВБП) и общей выживаемости (ОВ) в ряде исследований. В большинстве опубликованных работ схема назначения митотана определялась локальными протоколами, что подчеркивает необходимость валидации протокола по его назначению и создания унифицированного режима дозирования. Материалы и методы. Проведено одноцентровое проспективное исследование II фазы с использованием двухэтапного дизайна Симона. В исследование включали пациентов с местнораспространенным или метастатическим АКР, ECOG 0–1, ранее не получавших митотан. Первичная конечная точка — частота достижения терапевтической концентрации митотана (14–20 мкг/мл). Статистическая гипотеза предполагала увеличение частоты достижения терапевтической концентрации с 50 до 70 % (β = 0,2; α = 0,05). Вторичные конечные точки — частота объективного ответа и контроля болезни ≥ 6 мес, ВБП, ОВ, безопасность терапии. Митотан назначался в начальной дозе 2 г/сут с постепенной эскалацией каждые 3-5 дней на 0,5 г до 4 г/сут, с последующей коррекцией дозы в зависимости от его концентрации в крови. Все пациенты одновременно с митотаном получали стандартную платиносодержащую химиотерапию (EDP или EP/EC). Результаты. В исследование включено 47 пациентов: 27 мужчин (57,4 %) и 20 женщин (42,5 %). Все пациенты получали платиносодержащую химиотерапию — 45 (95,8 %) EDP, 2 — EP/EC. При медиане наблюдения 12,4 мес терапевтическая концентрация митотана достигнута в 72,3 % (n = 34) случаев, медиана времени до ее достижения — 4,3 мес (95 % ДИ 3,3–5,3 мес). Частота объективного ответа составила 29,7 % (n = 14), контроль заболевания ≥ 6 мес — 63,8 % (n = 30). Медиана ВБП — 8,4 мес (95 % ДИ 4,2–12,6), медиана ОВ — 24,6 мес (9,9–44,6). Профиль нежелательных явлений не отличался от ранее описанного. Выводы. Разработанный режим митотана обеспечивает быстрое и безопасное достижение терапевтической концентрации у большинства пациентов и может быть рекомендован для рутинной практики.
- 11 March 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (1)
Open AccessProspective, Single-Center, Phase II Study to Standardize the Mitotane Dosing Regimen in Combination with Platinum-Based Chemotherapy in the First-Line Treatment for Adrenocortical Cancer
Введение. Комбинация химиотерапии EDP (этопозида, доксорубицина, цисплатина) с митотаном является стандартом первой линии терапии адренокортикального рака (АКР). Достижение терапевтических концентраций митотана связано с улучшением выживаемости без прогрессирования (ВБП) и общей выживаемости (ОВ) в ряде исследований. В большинстве опубликованных работ схема назначения митотана определялась локальными протоколами, что подчеркивает необходимость валидации протокола по его назначению и создания унифицированного режима дозирования. Материалы и методы. Проведено одноцентровое проспективное исследование II фазы с использованием двухэтапного дизайна Симона. В исследование включали пациентов с местнораспространенным или метастатическим АКР, ECOG 0–1, ранее не получавших митотан. Первичная конечная точка — частота достижения терапевтической концентрации митотана (14–20 мкг/мл). Статистическая гипотеза предполагала увеличение частоты достижения терапевтической концентрации с 50 до 70 % (β = 0,2; α = 0,05). Вторичные конечные точки — частота объективного ответа и контроля болезни ≥ 6 мес, ВБП, ОВ, безопасность терапии. Митотан назначался в начальной дозе 2 г/сут с постепенной эскалацией каждые 3-5 дней на 0,5 г до 4 г/сут, с последующей коррекцией дозы в зависимости от его концентрации в крови. Все пациенты одновременно с митотаном получали стандартную платиносодержащую химиотерапию (EDP или EP/EC). Результаты. В исследование включено 47 пациентов: 27 мужчин (57,4 %) и 20 женщин (42,5 %). Все пациенты получали платиносодержащую химиотерапию — 45 (95,8 %) EDP, 2 — EP/EC. При медиане наблюдения 12,4 мес терапевтическая концентрация митотана достигнута в 72,3 % (n = 34) случаев, медиана времени до ее достижения — 4,3 мес (95 % ДИ 3,3–5,3 мес). Частота объективного ответа составила 29,7 % (n = 14), контроль заболевания ≥ 6 мес — 63,8 % (n = 30). Медиана ВБП — 8,4 мес (95 % ДИ 4,2–12,6), медиана ОВ — 24,6 мес (9,9–44,6). Профиль нежелательных явлений не отличался от ранее описанного. Выводы. Разработанный режим митотана обеспечивает быстрое и безопасное достижение терапевтической концентрации у большинства пациентов и может быть рекомендован для рутинной практики.
- Open Access
- 17 December 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 18-24
Efficacy of chemotherapy and targeted therapy for metastatic pheochromocytoma / paraganglioma: retrospective analysis
Introduction: Pheochromocytoma (PC) and paraganglioma (PG) are rare neuroendocrine tumors derived from adrenal chromaffin cells. The main options of systemic therapy for PC / PG are alkylating agent-based chemotherapy (ChT) and targeted therapy with sunitinib. There are no comparative data on the efficacy of these options, which became the purpose of this study.Materials and methods: This retrospective single-center study included patients over 18 y. o. who received ChT or targeted therapy for the first line treatment for metastatic PC / PG from September 2015 to August 2023.Results: The study included 33 patients (pts) who were divided into two groups — ChT (N = 18, 54.5 %) and targeted therapy (N = 15, 45.5%). In the ChT group, 12 pts (66.7%) received CVD regimen, 6 (33.3%) — temozolomide. In the targeted therapy group, 10 pts (66.7%) received sunitinib, 4 (26.7%) — pazopanib, and 1 (6.7%) — everolimus. Concurrent somatostatin analogues therapy was prescribed in 12 (66.7%) and 10 (66.7%) pts in the ChT and targeted therapy groups, respectively. Both groups were comparable by all main characteristics. Objective response was achieved in 11.11 % (N = 2) and 6.67 % (N = 1) [p=0.99], disease control > 6 months — 61.11 % and 60% (p = 0.99), biochemical response — 36.36% and 30% (p = 0.9) in the ChT and targeted therapy groups, respectively. Median PFS was 12.7 (2.9-22.3) in the ChT versus 12.9 months (2.3-26.5) in the targeted therapy group (p = 0.55). Median overall survival was not reached in both groups.Discussion: According to comparable efficacy of both treatment options and the indolent course of PC / PG, most patients do not require ChT in the 1st line of treatment. While choosing the 1st line therapy it is necessary firstly to take into account the safety profile of the drugs.
- 17 December 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 18-24
Open AccessEfficacy of chemotherapy and targeted therapy for metastatic pheochromocytoma / paraganglioma: retrospective analysis
Introduction: Pheochromocytoma (PC) and paraganglioma (PG) are rare neuroendocrine tumors derived from adrenal chromaffin cells. The main options of systemic therapy for PC / PG are alkylating agent-based chemotherapy (ChT) and targeted therapy with sunitinib. There are no comparative data on the efficacy of these options, which became the purpose of this study.Materials and methods: This retrospective single-center study included patients over 18 y. o. who received ChT or targeted therapy for the first line treatment for metastatic PC / PG from September 2015 to August 2023.Results: The study included 33 patients (pts) who were divided into two groups — ChT (N = 18, 54.5 %) and targeted therapy (N = 15, 45.5%). In the ChT group, 12 pts (66.7%) received CVD regimen, 6 (33.3%) — temozolomide. In the targeted therapy group, 10 pts (66.7%) received sunitinib, 4 (26.7%) — pazopanib, and 1 (6.7%) — everolimus. Concurrent somatostatin analogues therapy was prescribed in 12 (66.7%) and 10 (66.7%) pts in the ChT and targeted therapy groups, respectively. Both groups were comparable by all main characteristics. Objective response was achieved in 11.11 % (N = 2) and 6.67 % (N = 1) [p=0.99], disease control > 6 months — 61.11 % and 60% (p = 0.99), biochemical response — 36.36% and 30% (p = 0.9) in the ChT and targeted therapy groups, respectively. Median PFS was 12.7 (2.9-22.3) in the ChT versus 12.9 months (2.3-26.5) in the targeted therapy group (p = 0.55). Median overall survival was not reached in both groups.Discussion: According to comparable efficacy of both treatment options and the indolent course of PC / PG, most patients do not require ChT in the 1st line of treatment. While choosing the 1st line therapy it is necessary firstly to take into account the safety profile of the drugs.